Welcome to our dedicated page for BIOLARGO news (Ticker: BLGO), a resource for investors and traders seeking the latest updates and insights on BIOLARGO stock.
BioLargo, Inc. (BLGO) focuses on delivering sustainable technology-based products to address critical issues in water, food, agriculture, healthcare, and energy sectors. The company's subsidiary, BioLargo Water, Inc., is known for its advanced oxidation systems, including the AOS filter, designed to efficiently eliminate toxic contaminants in water. BioLargo has received the Technology Star Award for its breakthrough innovation in the oil industry and recognized as a technology innovation leader in the water treatment market. Additionally, the company owns a 50% interest in the Isan System, which has been honored as a top 50 water company for the 21st century.
BioLargo, Inc. (OTCQB:BLGO) has filed its Annual Report on Form 10-K for 2021, showcasing significant financial and commercial advancements. The company reported a 4% revenue increase to $2.53 million, despite a 14% year-over-year revenue decline in Q4. Total debt decreased from $2.9 million to $681,000, while net loss fell by 29% to $6.9 million. Key developments include partnerships for PFAS treatment technology and a successful market introduction of new products. An investor webcast will be held on April 4, 2022, to discuss further details and future growth opportunities.
BioLargo, Inc. (OTCQB:BLGO) announced progress on three key growth initiatives:
- The Minimal Liquid Discharge Water Treatment System successfully passed factory acceptance testing, demonstrating over 98% contaminant removal.
- The Aqueous Electrostatic Concentrator (AEC) for PFAS removal is advancing with ongoing studies and potential field trials.
- Collaborations with Ikigai Marketing Works are showing promise in the rollout of a new pet odor control product, exceeding initial expectations.
The company emphasizes its commitment to innovation and sustainability.
BioLargo, Inc. (OTCQB:BLGO) announced that its Aqueous Electrostatic Concentrator (AEC) successfully eliminated multiple PFAS compounds from municipal water in Southern California. PFAS, harmful chemicals linked to serious health concerns and persistent in the environment, are facing increased regulatory scrutiny. The AEC technology has shown the ability to reduce PFAS levels below quantification limits, confirming its efficacy in providing safe drinking water. This advancement is crucial as BioLargo prepares for commercial trials and sales, positioning itself as a leader in PFAS removal solutions.
BioLargo, Inc. (OTCQB:BLGO) is advancing the commercialization of its innovative wastewater treatment technology, the minimal liquid discharge system, developed for Garratt-Callahan. The company will use a full-scale prototype to treat simulated and actual industrial wastewater, aimed at optimizing performance before sales to Garratt-Callahan customers begin. This technology is designed to reduce wastewater volume and disposal costs, while also enhancing environmental sustainability. BioLargo emphasizes its commitment to sustainable solutions and innovation in wastewater treatment.
BioLargo, Inc. (OTCQB:BLGO) has entered into a manufacturer's representative agreement with ICS Group, focusing on the sale of its innovative water treatment technologies. This partnership marks a significant step in expanding BioLargo's commercial network. ICS Group will promote BioLargo's proprietary solutions, including the Advanced Oxidation System and the Aqueous Electrostatic Concentrator, designed for wastewater treatment and PFAS contamination removal. The deal also includes BioLargo's PFAS Testing Program and CupriDyne Clean odor control product.
BioLargo, Inc. (OTCQB:BLGO) has received a 'go decision' from its partner Ikigai Holdings to expand television advertising for its new pet odor control product, 'POOPH'. The decision follows successful test marketing results, indicating strong potential for the product's commercial success. Ikigai CEO Jane Pak highlighted positive early feedback and plans for an extensive marketing campaign post-Christmas. BioLargo CEO Dennis P. Calvert mentioned the partnership could generate significant revenue, with Ikigai managing product rollout and distribution.
BioLargo, Inc. (OTCQB:BLGO) has filed its Quarterly Report for Q3 2021, revealing a 7% increase in consolidated revenue to $712,000, largely driven by a 73% rise in the engineering division. The company's net loss decreased to $1.3 million, down from $2.1 million the previous year due to reduced interest expenses. Key progress includes successful PFAS treatment tests with prospective clients, completion of a prototype for Garratt-Callahan, and promising pilot results for the AOS technology, solidifying its position for future growth.
BioLargo, Inc. (OTCQB:BLGO) will host an investor webcast on November 17, 2021, at 8:00 AM PST / 11:00 AM EST, to discuss its financial results and recent commercial milestones. The event is public and will include a Q&A session. Investors can access the live stream and replay through the company's website. BioLargo specializes in sustainable environmental technologies, holding numerous patents and executing various projects, while also emphasizing partnerships and innovative solutions to environmental challenges.
BioLargo, Inc. (OTCQB:BLGO) announced a peer-reviewed article confirming the efficacy of its water treatment technology, the Advanced Oxidation System (AOS). Published in ACS ES&T Water, the study reveals that AOS generates highly energetic iodine molecules, enhancing disinfection efficiency. Currently being tested at a municipal wastewater facility, AOS demonstrates superior performance and lower energy consumption compared to traditional methods. The research employed advanced measurement techniques, establishing AOS as a significant advancement in sustainable water treatment technology.
BioLargo, Inc. (BLGO) shared a letter to stockholders on September 30, 2021, outlining strategic partnerships to enhance its market presence. Notably, BioLargo is launching a wastewater treatment product with Garratt-Callahan, aiming to sell 25-35 units within the first year. They also plan to commercially launch their PFAS treatment device, AEC, in early 2022. Additionally, a new consumer product partnership is underway with Ikigai Holdings. Overall, BioLargo is focusing on revenue growth and improving financial health, having significantly reduced debt while pursuing sustainable business solutions.
FAQ
What is the current stock price of BIOLARGO (BLGO)?
What is the market cap of BIOLARGO (BLGO)?
What does BioLargo, Inc. focus on?
What is BioLargo Water, Inc. known for?
What awards has BioLargo received?
What is Isan System?
